BioGend Therapeutics Co., Ltd. (TPEX:6733)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
38.40
-0.70 (-1.79%)
At close: Dec 5, 2025
6.08%
Market Cap 4.78B
Revenue (ttm) 212.43M
Net Income (ttm) -102.59M
Shares Out 124.36M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 205,001
Average Volume 206,537
Open 39.15
Previous Close 39.10
Day's Range 38.10 - 39.15
52-Week Range 23.20 - 49.15
Beta 0.19
RSI 41.82
Earnings Date Nov 7, 2025

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. researches, develops, and sells orthopedic medical equipment and related products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was incorporated in 2016 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 27
Stock Exchange Taipei Exchange
Ticker Symbol 6733
Full Company Profile

Financial Performance

In 2024, BioGend Therapeutics's revenue was 167.65 million, an increase of 52.53% compared to the previous year's 109.91 million. Losses were -116.47 million, -25.49% less than in 2023.

Financial Statements

News

There is no news available yet.